Long-term outcomes and cost effectiveness of high-dose dexamethasone for cardiac surgery: a randomised trial
Prophylactic intra-operative administration of dexamethasone may improve short-term clinical outcomes in cardiac surgical patients. The purpose of this study was to evaluate long-term clinical outcomes and cost effectiveness of dexamethasone versus placebo. Patients included in the multicentre, randomised, double-blind, placebo-controlled DExamethasone for Cardiac Surgery (DECS) trial were followed up for 12 months after their cardiac surgical procedure. In the DECS trial, patients received a single intra-operative dose of dexamethasone 1 mg.kg−1 (n = 2239) or placebo (n = 2255). The effects on the incidence of major postoperative events were evaluated. Also, overall costs for the 12-month postoperative period, and cost effectiveness, were compared between groups. Of 4494 randomised patients, 4457 patients (99%) were followed up until 12 months after surgery. There was no difference in the incidence of major postoperative events, the relative risk (95%CI) being 0.86 (0.72-1.03); p = 0.1. Treatment with dexamethasone reduced costs per patient by £921 [€1084] (95%CI £−1672 to −137; p = 0.02), mainly through reduction of postoperative respiratory failure and duration of postoperative hospital stay. The probability of dexamethasone being cost effective compared with placebo was 97% at a threshold value of £17,000 [€20,000] per quality-adjusted life year. We conclude that intra-operative high-dose dexamethasone did not have an effect on major adverse events at 12 months after cardiac surgery, but was associated with a reduction in costs. Routine dexamethasone administration is expected to be cost effective at commonly accepted threshold levels for cost effectiveness.
|Keywords||cost effectiveness, dexamethasone, inflammation, surgery|
|Persistent URL||dx.doi.org/10.1111/anae.13853, hdl.handle.net/1765/108692|
Dieleman, J.M. (J. M.), de Wit, G.A, Nierich, A.P, Rosseel, P.M.J, van der Maaten, J.M, Hofland, J, … Van Dijk, D. (2017). Long-term outcomes and cost effectiveness of high-dose dexamethasone for cardiac surgery: a randomised trial. Anaesthesia, 72(6), 704–713. doi:10.1111/anae.13853